Tag Archives: ENITH

Enicepatide “At Least as Good as Tirzepatide;” Roche ADA 2026 Investor Event

Roche hosted an investor event in conjunction with ADA 2026 and provided updates across its obesity pipeline, including future development plans for enicepatide and petrelintide (view slides). Notably, the company has also discontinued development of CT-868 for the obese + T1DM population, despite presenting positive Ph2 data during ADA. Below, FENIX provides highlights and insights from the investor webcast.

This content is for Read Less members only.

Already a member? Log in here

Roche and Sanofi Q1 ’26 Earnings; Topline Ph3 PIONEER TEENS Data; Hims & Hers Expands Integration to LillyDirect; Amgen Management Changes

A series of cardiometabolic-related news items has been observed from Roche, Novo Nordisk, Hims & Hers, Sanofi, and Amgen. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche and Sanofi Q4 ’25 earnings; New Fractyl Revita Data

Three cardiometabolic-related news items have been observed: Roche (view press release; view slides) and Sanofi (view press release; view slides; view infographic) hosted their respective Q4 ’25 earnings calls; and Fractyl Health announced 6-month results from its REMAIN-1 Midpoint Cohort for the Revita procedure (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here